CTOs on the Move

Regulus Therapeutics

www.regulusrx.com

 
Regulus is focused on the discovery and development of microRNA therapeutics. microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome.  A single microRNA can target and regulate up to hundreds of genes, and these genes are involved in biological networks or pathways.  Dysregulated microRNA expression is involved in the initiation of many complex multi-factoral diseases, including cancer, inflammatory disease, fibrosis, and metabolic disease. microRNA therapeutics are oligonucleotide medicines that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat  human ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.regulusrx.com
  • 10614 Science Center Dr
    San Diego, CA USA 92121
  • Phone: 888.734.8587

Executives

Name Title Contact Details

Funding

Regulus Therapeutics raised $10M on 06/21/2016
Regulus Therapeutics raised $15M on 05/07/2019

Similar Companies

Bioscience

Bioscience, Inc. is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spheryx

Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic CharacterizationTM of colloidal materials. Spheryx’s breakthrough proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, thereby offering unprecedented insights into these materials’ characteristics. Applications include research and development, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs.

Picometrics

Picometrics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alliance Bio

Alliance Bio is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.